IMIM. Parc de Salut Mar. Barcelona. Institut Hospital del Mar d'Investigacions Mèdiques

Annual report 2020

Innovative, Quality Biomedical Research

Innovative, Quality Biomedical Research

“2020 was a very unusual year. We supported our researchers to allow them to adapt their areas of research to the pandemic, and many of them submitted projects that have been funded and try to find new solutions to this pandemic.”

Joaquín Arribas. Director of Hospital del Mar Medical Research Institute (IMIM) and Research Director of Parc de Salut Mar

“All of us, health care personnel and scientists, reacted very quickly to adapt to the new reality and give of our best in response to society and to the scientific community.”

Olga Pané. Manager of Hospital del Mar-Parc de Salut Mar

Overview of the Year

Research Programs

Biomedical Informatics

Program Director: Ferran Sanz

5 groups

Computational methods to understand and predict biological phenomena related to human diseases, their diagnosis and pharmacological treatment.

“I am delighted to see an impressive program in biomedical informatics in IMIM. The program is implemented by a strong faculty with broad expertise and scientific interests covering a wide range of biomedical informatics. The success of IMIM in obtaining a substantial grant from the Innovative Medicines Initiative of the EU demonstrates their international recognition”.

Alvis Brazma

Head of Omics Section at EMBL-EBI, Senior Scientist at EMBL



Program Director: Joan Albanell Mestres

16 groups

Our research aims to deliver innovative findings for precision medicine and immunotherapy in cancer patients.

“IMIM has invested major resources in oncology, and I am really pleased to see that the plan is to continue in that direction and expand the capability of the institute to develop new oncology drugs and new oncology programs. The close partnership and proximity with Hospital del Mar and the clinical leadership are greatly contributing to effectively merging clinical and translational science. I am sure that this will make IMIM a leading player in the international oncology arena.”

Luca Gianni

President of Fondazione Gianni Bonadonna and Chairman of the Breast Cancer Research Committee Fondazione Michelangelo, Milan, Italy


Epidemiology and Public Health

Program Director: Jordi Alonso

11 groups

We translate our research into public health and clinical practice, and we innovate in the preventive and health care assessment fields.

“The Epidemiology and Public Health Program supports an impressive portfolio of multi-disciplinary research on a range of clinical and environmental/occupational topics. Ongoing research projects bring together studies at all stages of the translational pathway, allowing increased understanding of the burden of disease in the population, identification of risk factors, and the generation of evidence to support prevention/treatment strategies. Researchers contribute to national and international networks, and the program is developing the next generation of researchers through its undergraduate and postgraduate training program.”

Caroline Sabin

Professor of Medical Statistics and Epidemiology. Director, National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Blood Borne and Sexually Transmitted Infections, Institute for Global Health, University College London, UK



Program Director: Rafael de la Torre

15 groups

We support clinical research that, which should ultimately give us a better understanding of mental and neurodegenerative diseases.

“The IMIM Neurosciences Program includes 15 research groups with 158 staff members and has performed very well both in terms of scientific output (219 publications) and also by financing ongoing projects with a total of almost 10 million euros, much of which comes from European grants (e.g., Horizon 2020 and ERC). Fifteen new clinical trials, including phase 1 trials, were signed in 2020, witnessing the reputation of the Neuroscience program among industrial partners. Considering the general societal impact of the COVID-19 pandemic, these numbers are particularly impressive and signal a high level of optimism for the future of the IMIM Neurosciences program.”

Gitte Moos Knudsen

Professor at University of Copenhagen. Chair of Neurobiology Research Unit, Rigshospitalet and Chair of Center for Experimental Medicine Neuropharmacology. Copenhagen, Denmark


Translational Clinical Research

Program Director: Francesc Xavier Nogués

15 groups

We study the pathophysiology of a variety of disorders involving inflammatory processes in order to develop novel therapeutic approaches.

“The Clinical Translation Research Program gathers researchers and clinicians who provide their expertise to translational and clinical research projects to expand knowledge on pathophysiology, diagnosis and treatment to improve patient care. The multidisciplinary nature of the Program teams combined with a strong background in immuno-inflammation allows us to address immune/inflammatory-related disorders affecting a large range of organs and systems, including heart, lung, muscle, kidney, skin, bone, but also neurodegenerative diseases and cancers.”

Gervaise Loirand

Inserm Team Leader III. Deputy Director of the UMR Inserm 1087 / Cnrs 6291. Université de Nantes, France


Relevant Projects

“Although the IMIM result in the Instituto de Salud Carlos III project call for projects was not as good as other years, IMIM has been able to obtain funding for COVID research projects to a large extent. This highlights the tendency of the institution to continue obtaining European projects and other notable funding, such as CRIS projects.”
Marta López Otero.

Marta López Otero

Head of IMIM Research Department

Research Projects by Program





Biomedical Informatics


Translational Clinical Research


Epidemiology and Public Health




Neurosciences 9,569,519.46
Cancer 8,623,366.95
Biomedical Informatics 4,910,003.89
Translational Clinical Research 4,736,691.15
Epidemiology and Public Health 3,245,015.35
Other 65,115.00

Outstanding Projects

Agencia Estatal de Investigación.
Development of a Therapy for Fragile X Syndrome
Rafael de la Torre.

Principal investigator

Rafael de la Torre

The public-private consortium formed by the biotech company Connecta Therapeutics, the Centre for Genomic Regulation (CRG), and the Hospital del Mar Medical Research Institute (IMIM) has received a grant from the Spanish National Innovation Agency to develop an innovative treatment for fragile X syndrome, the most common form of hereditary intellectual disability. In the first phase, CRG will conduct complementary pharmacology studies on the Connecta Therapeutics CTH120 molecule, which preclinical studies found to be a good neuroplasticity modulator. IMIM will then start a Phase I clinical trial.

Cris. Cancer Foundation.
Tailoring anti-EGFR Therapy in Metastatic Colorectal Cancer: Clonal Dynamics and the Immune System
Clara Montagut.

Principal investigator

Clara Montagut

The project is funded by CRIS Cancer Foundation and the main objective is to better understand the mechanisms of resistance to anti-EGFR treatments in metastatic colorectal tumors. The study aims to characterize the role of immunity and clonal dynamics using liquid biopsy. The project integrates three clinical trials, notably the CITRIC clinical trial that we have recently opened, as well as a preclinical part with in vitro and in vivo models.

eTRANSAFE: Enhancing Translational Safety Assessment through Integrative Knowledge Management
Ferran Sanz.

Principal investigator

Ferran Sanz

The five-year project coordinated by IMIM aims to develop an advanced data integration infrastructure together with innovative computational methods to improve the security in drug development process. The project is funded by the Innovative Medicines Initiative (IMI2) together with the pharmaceutical industry.

Instituto de Salud Carlos III.
Immune Checkpoints in the Regulation of Natural Killer Cell Responses in Multiple Sclerosis
José Enrique Martínez.

Principal investigator

José Enrique Martínez

The project is led by IMIM researchers and funded by Fondo de Investigación Sanitaria. Its main objective is to study the clinical and immunological implications of NK cell regulatory mechanisms based on immune checkpoint inhibitors in multiple sclerosis (PD-1, CTLA-4, TIGIT, Tim-3, NKG2A, Lag3).

Mind Covid.
MIND/COVID: Mental Health Impact and Needs Associated With COVID-19: A Comprehensive National Evaluation in Spain
Jordi Alonso.

Principal investigator

Jordi Alonso

The project is led by IMIM researchers and has a team of experts from more than 20 Spanish institutions. Its objective is to study the mental health of healthcare professionals and other vulnerable groups, as well as in patients with COVID-19 and in a sample of the general Spanish adult population. It is funded by the Instituto de Salud Carlos III of the Ministry of Science and Innovation. (FEDER COV20 / 00711)

Clinical Trials

“Despite the extraordinary impact that the pandemic has had on the activity of our institution, the number of ongoing clinical trials during 2020 has been higher than in previous years, and 150 other new trials have also been signed, demonstrating the tremendous effort made by our researchers.”
Miguel Pera.

Miguel Pera

Medical Director of Hospital del Mar-Parc de Salut Mar

Clinical Trials Signed in 2020

65 Translational Clinical Research
58 Cancer
15 Neurosciences
10 Other (Hospital and management)
2 Epidemiology and Public Health
Translational Clinical Research 65
Cancer 58
Neurosciences 15
Other (Hospital and management) 10
Epidemiology and Public Health 2

Total 150

Clinical Trials, 2016-2020

Relevant Clinical Trials

Fundamental phase-III multicenter, randomized double-blind, placebo-controlled trial with two parallel arms to research the efficacy and safety of human recombinant alkaline phosphatase for the treatment of patients with sepsis-associated acute kidney injury.

Sepsis is the main cause of acute kidney injury and is one of the main causes of death. In fact, patients with sepsis-associated acute kidney injury have high mortality and morbidity and are at risk of developing chronic kidney disease. This trial is based on the administration of alkaline phosphatase in these patients. It is an enzyme present in many cells and organs and has detoxifying effects. The initial results of this clinical trial show that the use of human recombinant alkaline phosphatase increases survival in patients with acute sepsis.

Principal investigator

Clara Vilà Vilardell

Open phase Ia/Ib trial on increasing dosage to determine the safety and pharmacokinetics of MTIG7192A in single-drug therapy and in combination with atezolizumab in patients with locally advanced or metastatic tumors.

Phase 1 clinical trial with a novel design to analyze the antitumor activity of a new immunotherapy drug (tiragolumab) in combination with an already approved immunotherapy (atezolizumab) in various solid tumors where immunotherapy is already a standard treatment, with the aim of minimizing the resistance that can appear with this treatment when it is administered in single-drug therapy.

Principal investigator

Alejo Rodríguez-Vida


The PENSA Study is a clinical trial aiming at preventing cognitive decline in APOE-ɛ4 carriers with subjective cognitive decline. The proposed clinical trial design evaluates the efficacy of epigallocatechin-3-gallate (EGCG) in the context of a personalized medicine approach including a multimodal intervention looking at improving person-centered outcomes in this population.

Principal investigator

Rafa de la Torre

Study of costs associated with the treatment of neovascular age-related macular degeneration (ARMD) in two tertiary hospitals in Spain.

The study is part of a research agreement with Novartis that will make it possible to analyze the use of resources related to the diagnosis and treatment of age-related macular degeneration (ARMD) at Parc de Salut Mar. The study analyzes the number and cost of associated visits and tests and the pharmacologic cost of the treatment. It also links treatment intensity with maintaining visual ability during treatment in the study period: 2017-2018.

This research agreement also includes Hospital Miguel Servet, Zaragoza.

Principal investigators

Francesc Cots Reguant
Pere Ortiz Sagristà


“IMIM research programs present major synergies and, above all, remarkable scientific quality. I believe that we are in a very good position so that, in the near future, IMIM will be an undisputed leader in cutting-edge areas of translational biomedical research, both nationally and internationally. I also believe that, because of its intrinsic value and because of the scientific and technological campus that surrounds it, IMIM will be a very powerful pole of attraction for young talent and businesses.”
Xosé R. Bustelo.

Xosé R. Bustelo

CSIC Research Professor, Salamanca Cancer Research Center (CSIC-University of Salamanca). Vice-director, Salamanca Cancer Research Center. Coordinator, Mechanisms of Tumor Progression Program of the Spanish Network for Biomedical Research in Cancer (CIBERONC)

Publications by Program

933 publications (Indexed and non indexed)
1,151 publications (Indexed and non indexed)
2019 2020
Translational Clinical Research 296 276
Neurosciences 126 175
Epidemiology and Public Health 225 210
Cancer 164 201
Biomedical Informatics 24 27
Total indexed publications 823 922
186 1st decile 441 1st quartile

Bibliometric indicators


224 1st decile 514 1st quartile

Bibliometric indicators


Relevant Publications

Magri G.

Magri G., Cerutti A.

IgA Summons IgG to Take a Hit at HIV-1. Cell Host Microbe 2020; 27(6): 854-856.

Patricia Robledo.

Guinart D, Moreno E, Galindo L, Cuenca-Royo A, Barrera-Conde M, Pérez EJ, Fernández-Avilés C, Correll CU, Canela EI, Casadó V, Cordomí A, Pardo L, de la Torre R, Pérez V, Robledo P.

Altered Signaling in CB1R-5-HT2AR Heteromers in Olfactory Neuroepithelium Cells of Schizophrenia Patients is Modulated by Cannabis Use. Schizophr Bull. 2020 Dec 1;46(6):1547-1557. doi: 10.1093/schbul/sbaa038. PMID: 32249318; PMCID: PMC7846100.

M. Fitó.

Castañer O, Pintó X, Subirana I, Amor AJ, Ros E, Hernáez Á, Martínez-González MÁ, Corella D, Salas-Salvadó J, Estruch R, Lapetra J, Gómez-Gracia E, Alonso-Gómez AM, Fiol M, Serra-Majem L, Corbella E, Benaiges D, Sorli JV, Ruiz-Canela M, Babió N, Sierra LT, Ortega E, Fitó M.

Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease. J Am Coll Cardiol. 2020 Dec 8;76(23):2712-2724. doi: 10.1016/j.jacc.2020.10.008.

Anna Bigas.

Sentís I, González S, Genescà E, Garcia V, Muiños F, González C, López-Arribillaga E, González J, Fernández-Ibarrondo L, Mularoni L, Espinosa L, Bellosillo B, Ribera JM*, Bigas A*, González-Pérez A, López-Bigas N*.

The evolution of relapse of adult T cell acute lymphoblastic leukemia. Genome Biol 2020; 21(1): 284. *Co-correspondings.

Jana Salent.

Rodríguez-Espigares I, Torrens M, Tiemann JKS, Aranda D, Ramírez-Anguita JM, Stepniewski T, Worp N, Varela-Rial A, Morales A, Medel B, Pándy-Szekeres G, Mayol E, Giorgino T, Carlsson J, Deupi X, Filipek S, Filizola M, Gómez-Tamayo JC, González A, Gutiérrez-de-Terán H, Jiménez-Rosés M, Jespers W, Kapla J, Khelashvili G, Kolb P, Latek D, Martí-Solano M, Matricon P, Matsoukas MT, Miszta P, Olivella M, Pérez-Benito L, Provasi D, Ríos S, R Torrecilla, Sallander J, Sztyler A, Vasile S, Weinstein H, Zachariae U, Hildebrand PW, De Fabritiis, Sanz F, Gloriam DE, Cordomí A, Guixà-González R, Selent J.

GPCRmd uncovers the dynamics of the 3D-GPCRome. Nat Meth 2020; 17(8): 777-787.

Core Facilities

“2020 was like an earthquake, forcing us to adapt rapidly to the new research needs: new sample circuits, new biosafety protocols for transport and for processing COVID-19 patient samples. All of this was done to allow COVID-19 research to proceed without blocking other research requirements. This was a real challenge that has shown us our own capabilities as a core facility.”
Núria Somoza i Abelló.

Núria Somoza i Abelló

Coordination of IMIM Scientific and Technological Platforms


A public non-profit organization that gathers various biological sample collections for biomedical research. MARBiobanc is organized as a technical unit with standards of quality, order, and purpose.

  • 137 requests

    (30 clinical trials and 107 research projects)

  • 42 other services
  • 3,174 samples approved
  • 1 funding
  • 11 publications

    with samples from MARBiobank

IMIM Internal Facilities

Radioactive Facilities
Cell-Culture Facilities
Cryopreservation Unit
Bioluminescence/Fluorescence Facility (IVIS)

Other PRBB Shared Facilities


“Despite the major difficulties of 2020, fundraising was particularly good. This is mainly due to two aspects: the success of the proposals submitted to the national calls for projects in 2019 and the tremendous ability of our researchers to design and submit proposals of major translational interest to the unexpected COVID-19 calls.”
Vanesa Nogales.

Vanesa Nogales

Deputy Director, IMIM

Sources of Funding

Competitive 2019


Competitive 2020


2019 2020
National grants 5,513,696.45 7,561,066.09
Public bodies of the Generalitat 1,038,441.86 1,505,355.87
European Union 727,126.16 1,086,738.44
Other International Grants 1,013,446.11 975,035.95
Total 8,294,729.58 11,130,216.95
Non competitive 2019


Non competitive 2020


2019 2020
Clinical Trials 4,169,116.70 4,304,540.46
Research contracts 2,813,634.07 2,341,533.71
Analytics and Quality Control 1,386,412.32 916,298.07
Donations 854,593.24 719,466.72
Others 275,844.34 116,937.92
Technology transfer 269,142.25 82,938.90
Courses and congresses 39,840.25 3,223.14
Total 9,810,602.17 8,486,958.92
Trustees contribution (Generalitat de Catalunya)




Total 2020




Non competitive


Trustees contribution (Generalitat de Catalunya)


Competitive 11,130,216.95
Non Competitive 8,486,958.92
Trustees contribution (Generalitat de Catalunya) 3,133,333.84

Outstanding Competitive Grants

Improving Cognitive Performance in Down Syndrome Patients (ICOD)
Rafael de la Torre.

Principal investigator:

Rafael de la Torre





Horizon 2020

Beyond Classical Conditioning: Hippocampal Circuits in Higher-Order Memory Processes (HighMemory)
Arnau Busquets.

Principal investigator:

Arnau Busquets





European Research Council (ERC)


“One of the priorities of IMIM in order to achieve scientific excellence is attracting talent. In 2020, several actions were taken in this direction: the call for an R4 post, which was open internationally, thorough assessments of candidatures for R3 research posts from public grants to ICREA grants, etc. This has resulted in IMIM taking on two researchers of excellence: Dr. Jana Selent and Dr. Patrick Welz. Furthermore, some very important appointments were made in 2020, such as that of Dr. Anna Bigas, Scientific Director of CIBERONC and Deputy Director of the IJC Preclinical Research Program, and that of Dr. Mar Albà, the new Director of the IMIM Biomedical Informatics Research Program.”
Joaquín Arribas.

Joaquín Arribas

Director of IMIM and Research Director of PSMAR

Dr. Mar Albà

Dr. Mar Albà, new director of the Biomedical Informatics Research Programme (GRIB), a joint research program of IMIM and UPF.

“I have been a member of the program for the past 20 years, a period in which the program has successfully expanded under the direction of Ferran Sanz. I am pleased to have the opportunity to take the lead and contribute to increasing the visibility of women in executive positions”.

Dr. Anna Bigas

Dr. Anna Bigas, elected Scientific Director of the CIBER of Oncology (CIBERONC), Deputy director of preclinical research at the Josep Carreras Leukaemia Research Institute.

"This is a fantastic challenge to promote collaborative research at the National level through CIBERONC and to locally push high quality hematology research through my second affiliation with the Josep Carreras Leukaemia Research Institute".

Dr. Jana Salent

Dr. Jana Selent, obtained an R4 position (Leading Researcher) from the first IMIM R4 position call.

"Becoming an established R4 researcher at IMIM has been highly competitive and I am very proud of the recognition of my achievements in the field of structural biology and cell signal transduction. This new position provides me with a great opportunity to develop existing research lines but also new ideas, projects, and collaborations in a stable multidisciplinary research environment".

Dr. Patrick Welz

After the External Scientific Advisory Board evaluation, Dr. Patrick Welz was selected to join IMIM with a Ramon y Cajal contract as a R3 Researcher.

"I am grateful for having been offered the opportunity to join the IMIM as a principal investigator, which allows me to develop my own research lines, to apply my ideas in a clinically relevant setting and to establish myself as an independent scientist".


Total 754

Translational Clinical Research




Epidemiology and Public Health


Biomedical Informatics






Core facilities




Translational Clinical Research 213
Cancer 158
Epidemiology and Public Health 114
Biomedical Informatics 31
Neurosciences 158
Hospital 22
Core facilities 17
Management 41

Researchers by Gender

  • Researcher
  • Collaborating Researcher
  • Postdoctoral
  • Predoctoral
Researcher Collaborating Researcher Postdoctoral Predoctoral
Women 74 81 63 42
Men 99 58 32 17
Total 173 139 95 59

Research Profile

  • R4 Leading Researcher 
  • R3 Established Researcher 
  • R2 Recognized Researcher
  • R1 First Stage Researcher
R4 Leading Researcher R3 Established Researcher R2 Recognized Researcher R1 First Stage Researcher
Women 21 40 132 67
Men 49 39 82 39
Total 70 79 214 103
Sustainable Development Goals.

Communication and Public Engagement

“The media and the general public see IMIM as a trustworthy partner. The quality of the institute's communication contents and activities paired with the commitment of its people are highly appreciated by the park and all audiences. For the PRBB, IMIM is an essential and valued ally."
Reimund Fickert.

Reimund Fickert

Communication & Business Development. Barcelona Biomedical Research Park (PRBB)


Press releases


News appereances










Web 1,836
Press 343
Radio 100
TV 30
Press releases


News appereances










Web 1,160
Press 593
Radio 75
TV 32

Press Releases With the Greatest Impact

Nearly half of all health care professionals in Spain presented a high risk of mental disorder during the first COVID-19 wave

305 impacts

Gemma Vilagut, Jordi Alonso, Philippe Mortier i Víctor Pérez


COVID-19 affects the poorer areas of Barcelona more

146 impacts

Maria Grau

El País

Physical activity changes how our DNA acts

88 impacts

Alba Fernández Sanlés and Roberto Elosua


Virgin olive oil enriched with its own anti-oxidants prevents cholesterol build-up

65 impacts

Montserrat Fitó

Regió 7

Some of the principal treatments for osteoporosis may reduce the incidence of COVID-19

57 impacts

Josep Blanch and Jordi Monfort

Catalunya Ràdio

Two heart-damage markers identified as risk predictors in patients with COVID-19

51 impacts

Jaume Marrugat and Beatriz Vaquerizo


Website and Social Media




1,302 new followers

Top tweet 10.9 K impressions

Top publication 2,864 impressions


For the general public
Our Brain, That Great Unknown Organ. Cycle of Talks in Public Libraries
  • 20/01/2020: Getting to Know the Brain (Mara Dierssen and Jordi Peña)
  • 27/01/2020: Stroke: Before, During, and After (Jaume Roquer and Esther Duarte)
  • 03/02/2020: Eating and Living With the Brain in Mind (Anna Boronat, Thais Lorenzo and Natàlia Soldevila)
  • 10/02/2020: Why Does the Brain Sleep? (Rodrigo Rocamora and Ion Álvarez)
  • 17/02/2020: The Addicted Brain (Rafael Maldonado and Marta Torrens)
  • 24/02/2020: Emotions and Cognition in the Brain (Joan Deus and Vicky Puig)
  • 02/03/2020: Why do we get Headaches? (Elisa Cuadrado and Gloria Villalba)
  • 09/03/2020: Tips for Good Mental Health (Víctor Pérez and Daniel Bergé)

Total: 1,500 attendees

More info

26-31 October PRBB Virtual Open Day


  • Video: We are scientists
  • Virtual lab tours
  • Live sessions from the research centers
  • Failed experiments

11 February International Day of Women and Girls in Science

Campaign to raise visibility of gender bias in science, promote scientific vocations, and eliminate stereotypes.

More info

For students
Bringing Science Closer to Secondary Schools Project (ACCÉS)
  • 3 in-person visits
  • 4 virtual visits
  • 5 participating labs

Total: 170 students


Support campaigns of Fundació Amics de l’Hospital del Mar for research.

Sempre Endavant (2020)

Crowdfunding campaign to support COVID-19 research

Marina Walktrail (2020)

Nordic walking sports event organized to support the TV3 Marathon on COVID-19 research.



"The COVID-19 pandemic has put society, the health care system, and research centers to the test. The appearance of a new infectious disease with a high transmission rate and potential severity has forced many researchers to concentrate their efforts on this new entity. This reaction is understandable given the research centers’ mission to serve society. In the case of Hospital del Mar and IMIM, despite the tremendous pressure on patient care, many research initiatives were carried out by all the research programs. Several projects have obtained competitive grants and are beginning to show results and have laid the foundations for new areas of study for the coming years."
Juan Pablo Horcajada.

Juan Pablo Horcajada
Head of the Infectious Diseases Department

COVID-19 Competitive Projects by Program

Biomedical Informatics


Epidemiology and Public Health


Translational Clinical Research






Biomedical Informatics 3
Epidemiology and Public Health 7
Translational Clinical Research 5
Neurosciences 1
Other 2

Initiatives Carried Out


  • Follow-up committee
  • Weekly meetings with the IRISCAT director and managers
  • Unit for support for research on COVID-19

Adaptations of digital resources:

  • More than 10 online tools to facilitate working from home
  • Tool for managing in-person activity

Research initiatives:

  • More than 50 proposals processed
  • 7 grants awarded

Other initiatives:

  • Constitution of a COVID-19 biobank in collaboration with LRC
  • Collaboration with the ORFEU project
  • IMIM online seminars
  • Donation of material to the hospital and telephone call by volunteers

COVID-19 Projects

Project MIND/COVID To protect healthcare workers

Led by Dr. Jordi Alonso

More info "Project MIND/COVID To protect healthcare workers"

Applying artificial intelligence to improve COVID-19 diagnosis and treatment

Led by  Dr. Max Hardy and Dr. Jordi Soriano

More info "Applying artificial intelligence to improve COVID-19 diagnosis and treatment"

Discovering the immunity footprint of the virus

Led by Dr. Ramon Gimeno

More info "Discovering the immunity footprint of the virus"

Improving pandemic control with remote monitoring

Led by Dr. Maria Grau

More info "Improving pandemic control with remote monitoring"

Immunotherapy for COVID-19 patients and as a preventive treatment for at-risk individuals

Led by Dr. Giuliana Magri

More info "Immunotherapy for COVID-19 patients and as a preventive treatment for at-risk individuals"

Looking for already available and effective therapeutic solutions

Led by Dr. Jana Selent

More info "Looking for already available and effective therapeutic solutions"

Tool for preventing respiratory complications in COVID-19 patients

Led by Dr. Robert Güerri

More info "Tool for preventing respiratory complications in COVID-19 patients"

Reducing mortality in COVID-19 patients with prior cardiovascular risk

Led by Dr. Jaume Marrugat

More info "Reducing mortality in COVID-19 patients with prior cardiovascular risk"

Effects of immunodepressive contaminants on COVID-19 patients

Led by Dr. Miquel Porta

More info "Effects of immunodepressive contaminants on COVID-19 patients"

Stem4COVID, innovative project providing hope for discovery of new treatments

Led by Juan Pablo Horcajada and Laura Batlle

More info "Stem4COVID, innovative project providing hope for discovery of new treatments"

About Us

Inaugurated in 1948 by Dr. Alexander Fleming, the Hospital del Mar Medical Research Institute (IMIM) is a center of excellence for biomedical and health research.

IMIM is part of the Parc de Salut Mar consortium, and it is made up of more than 700 professionals, with a mixed composition of IMIM researchers and clinical researchers from Hospital del MAR and other academic researchers from UPF and UAB.

IMIM has the recognition of CERCA as a Catalan Research Institute of Excellence, ISCIII as Health Research Institute and HRS4R with the HR Excellence in Research.

Its proximity to Hospital del Mar and the Campus Universitari Mar, and its location in a solid scientific ecosystem like PRBB, means that IMIM is in a privileged biomedical enclave in Barcelona.

IMIM’s translational research is carried out through five well-structured research programs: epidemiology and public health, neuroscience, cancer, biomedical informatics, and clinical translational research programs.

Our Mission

To conduct excellent translational research to be an international gold standard in biomedical research.

Future Challenges

  • Excellence in scientific activity through internationalization and attracting talent
  • Sustainable growth through cost-effective investment of resources and promotion of development
  • Seamless linkage to society through highly translational research aligned with PSMAR's strengths



Minister of Health

Alba Vergés Bosch

First Vice-president

Minister of Business and Knowledge

Ramon Tremosa Balcells

Second Vice-president

Vice-president of the Governing Council of Barcelona Mar Health Park Consortium

Davide Malmusi


Rector of Universitat Autònoma de Barcelona

Javier Lafuente Sancho

Rector of Universitat Pompeu Fabra

Jaume Casals Pons

General Director for Research Ministry of Business and Knowledge

Joan Gómez Pallarès

Appointed by the Ministry of Health

Robert Fabregat Fuentes

Appointed by the Barcelona Mar Health Park Consortium

Julio Pascual, Olga Pané Mena, Josep Aumatell, Narcís Pérez de Puig (acting Secretary)

Appointed by Universitat Autònoma de Barcelona

Armand Sánchez Bonastre

Appointed by Universitat Pompeu Fabra

José García Montalvo

Executive Committee


Robert Fabregat Fuentes


General Research Director Ministry of Business and Knowledge

Joan Gómez Pallarès

Appointed by Universitat Autònoma de Barcelona

Armand Sánchez Bonastre

Appointed by Universitat Pompeu Fabra

José García Montalvo

Appointed by the Barcelona Mar Health Park Consortium

Olga Pané Mena, Narcís Pérez de Puig (acting Secretary)

Scientific Advisory Board (SAB)


Deputy Director of the Cancer Research Center (CIC), University of Salamanca-CSIC (Salamanca, Spain)

Xosé R Bustelo  PhD


DR1 Inserm Team leader III "Signaling and vascular and pulmonary pathophysiology", Deputy director of the UMR Inserm 1087 / Cnrs 6291 L'Institut du Thorax. Université de Nantes. France

Gervaise Loirand

Chair, Professor, MD, DMSc. Dept. Neurology and Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet, Denmark

Gitte Knudsen

Functional Genomics Senior Team Leader and Senior Scientist. EMBL-EBI, UK.

Alvis Brazma

Professor of Medical Statistics and Epidemiology. Infection & Population Health, Institute for Global Health. Faculty of Pop Health Sciences. UCL Principal Supervisor, UCL Subsidiary Supervisor. University College London, UK.

Caroline Sabin

Milan, Italy. Director, Medical Oncology, Head of the New Drug Development Laboratory of Clinical Pharmacology. Ospedale San Raffaele. President, Michelangelo Foundation.

Luca Gianni


Public Funders